SPAC Ash­ing­ton In­no­va­tion plans to ac­quire dor­mant biotech Celixir and lead heart fail­ure pro­gram for $172M

Lon­don-based SPAC Ash­ing­ton In­no­va­tion is plan­ning to ac­quire dor­mant, UK-based biotech Celixir for $172 mil­lion (£135 mil­lion) in an all-share trans­ac­tion, tak­ing over its lead …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER